Unified Parkinson's Disease Rating Scale (UPDRS) Successfully switched means: UPDRS II+III baseline score >20 without a relative worsening of UPDRS II+III score > 15% from baseline or UPDRS II+III baseline score <=20 without an absolute worsening of UPDRS II+III score > 3 from baseline UPDRS II+III ranging from 0 (normal) to 160 (severe). UPDRS part II measures activities of daily living, part III measures motor symptoms

Patients from Full Analysis Set (FAS included all patients who were dispensed study medication, had received at least one dose of study drug and had provided any post-baseline efficacy assessment) and who maintain the final dose of the previous study

UPDRS II+III ranging from 0 (normal) to 160 (severe). UPDRS part II measures activities of daily living, part III measures motor symptoms

Patients from FAS with values of UPDRS II+III at week 80

A response means an improvement of >=20% in UPDRS II+III from OL baseline UPDRS II+III ranging from 0 (normal) to 160 (severe). UPDRS part II measures activities of daily living, part III measures motor symptoms

Patients from FAS with values of UPDRS II+III at week 80

A patient was considered as successfully switched if he/she has converted to ER without a worsening of off time by more than 12.5% from baseline. Off-time is based on patient diary data and describes a period when the patient experiences increased parkinsonian symptoms (e.g. immobility or inability to move with ease).

Patients from FAS and who maintain the final dose of the previous study

Percentage off-time based on patient diary data, percentage ranging from 0 (best case) to 100 (worst case). Off-time describes a period when the patient experiences increased parkinsonian symptoms (e.g. immobility or inability to move with ease).

A negative change implies improvement

Patients from FAS with values of UPDRS II+III at week 80

Response means >=20% improvement relative to OL baseline in the % off-time during waking hours

Patients from FAS with values of off time during waking hours at 80 weeks

Percentage on-time based on patient diary data, percentage ranging from 0 (worst case) to 100 (best case). On-time describes a period when the patient has no symptoms of off-time and is not asleep. A positive change implies improvement.

Patients from FAS with values of on time during waking hours at week 80

Percentage on-time with non troublesome dyskinesia based on patient diary data, percentage ranging from 0 (worst case) to 100 (best case). On-time describes a period when the patient has no symptoms of off-time and is not asleep. A positive change implies improvement

Patients from FAS with values of on time during waking hours at week 80

Percentage on-time without dyskinesia or with non troublesome dyskinesia based on patient diary data, percentage ranging from 0 (worst case) to 100 (best case). On-time describes a period when the patient has no symptoms of off-time and is not asleep. A positive change implies improvement

Patients from FAS with values of on time during waking hours at week 80

Percentage on-time with troublesome dyskinesia based on patient diary data, percentage ranging from 0 (worst case) to 100 (best case). On-time describes a period when the patient has no symptoms of off-time and is not asleep. A positive change implies improvement

Patients from FAS with values of on time during waking hours at week 80

Clinical Global Impression of Improvement (CGI-I), CGI-I scores ranging from '1' (very much improved) to '7' (very much worse). For patients previously treated with Placebo, all patients with at least "much improved" were considered as responders. For patients previously treated with PPX ER or IR, all patients with no change to very much improved were considered as responders

Patients from FAS with values of CGI-I at week 32

Patient Global Impression of Improvement (PGI-I), PGI-I scores ranging from '1' (very much better) to '7' (very much worse). For patients previously treated with Placebo, all patients with at least "much better" were considered as responders. For patients previously treated with PPX ER or IR, all patients with no change to very much better were considered as responders

Patients from FAS with values of PGI-I at week 32

Patient Global Impression of Improvement (PGI-I) for early morning off symptoms, PGI-I scores ranging from '1' (very much better) to '7' (very much worse). For patients previously treated with Placebo, all patients with at least "much better" were considered as responders. For patients previously treated with PPX ER or IR, all patients with no change to very much better were considered as responders

Patients from FAS with values of PGI-I for early morning off symptoms at week 32

UPDRS I ranging from 0 (normal) to 16 (severe). UPDRS I measures Mentation, Behavior and Mood

Patients from FAS with values of UPDRS I at week 80

UPDRS II ranging from 0 (normal) to 52 (severe). UPDRS Part II is calculated as the average of UPDRS part II at on and UPDRS part II at off-period for each of the 13 activities

Patients from FAS with values of UPDRS II at week 80

UPDRS III ranging from 0 (normal) to 108 (severe). UPDRS part III measures motor symptoms

Patients from FAS with values of UPDRS III at week 80

UPDRS IV ranging from 0 (normal) to 23 (severe). UPDRS IV measures complications of therapy

Patients from FAS with values of UPDRS IV at week 80

PFS-16 (Parkinson fatigue scale) ranging from 16 (better perceived health status) to 80 (severe symptoms of the disease) measuring aspects of fatigue that are relevant to patients with PD

Patients from FAS with values of PFS-16 score at week 80

Patients from FAS with documentation of levodopa (L-DOPA) daily dose at week 80

Patients from Treated Set (all patients who were dispensed study drug and were documented to have at least one dose of investigational treatment) and treated until week 80

The Treated Set (TS) included all patients who were dispensed study drug and were documented to have at least one dose of investigational treatment

The aim of this study was to obtain long-term safety and tolerability data on pramipexole ER, in patients who have previously completed a pramipexole double blind study in advanced Parkinson's Disease (PD) (248.525 (NCT00466167)). Therefore these items were considered as a safety evaluation.

Patients from Treated Set (defined as all patients who were dispensed study drug and were documented to have at least one dose of investigational treatment)

Vital Signs Treated Set - All participants treated with study drug and have both baseline and week 80 vital sign data

Vital Signs Treated Set - All participants treated with study drug and have both baseline and week 80 vital sign data

Vital Signs Treated Set - All participants treated with study drug and have both baseline and week 80 vital sign data

Vital Signs Treated Set - All participants treated with study drug and have both baseline and week 80 vital sign data

Vital Signs Treated Set - All participants treated with study drug and have both baseline and week 80 vital sign data

Vital Signs Treated Set - All participants treated with study drug and have both baseline and week 80 vital sign data

Vital Signs Treated Set - All participants treated with study drug and have both baseline and week 80 vital sign data

Vital Signs Treated Set - All participants treated with study drug and have both baseline and week 80 vital sign data

ESS Total score ranges from zero (best) to 24 (worst); scale has 8 items, each rated from zero (no chance of dozing) to 3 (high chance of dozing)

The mMIDI is a semi-structured interview designed to assess impulsive control disorders. The scale was modified to focus behaviors of: pathological gambling, compulsive buying and compulsive sexual behavioral.

Treated Set - all patients dispensed drug and documented to have taken at least one dose